Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinson's disease

Brain Research

Volumn 1625, Issue , 2015, Pages 255-274

  Yao, Ning ^a   Wu, Yanhong ^a,b   Zhou, Yan ^a   Ju, Lili ^a   Liu, Yujun ^a   Ju, Rongkai ^a   Duan, Deyi ^a   Xu, Qunyuan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Locus coeruleus; Microglia; Parkinson'sdisease; Striatum; Substantianigra

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; CHEMOKINE RECEPTOR CCR2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTROPHIC FACTOR; NORADRENALIN; ACTIN BINDING PROTEIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AIF1 PROTEIN, MOUSE; BENZYLAMINE DERIVATIVE; CALCIUM BINDING PROTEIN; CYCLOOXYGENASE 2; CYTOKINE; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM INJURY; CELL FUNCTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; LOCUS CERULEUS; MALE; MICROGLIA; MORPHOLOGY; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; CELL CULTURE; COCULTURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; INJURIES; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PHYSIOLOGY;

ADRENERGIC AGENTS; ANIMALS; BENZYLAMINES; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; LOCUS COERULEUS; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MICROGLIA; NERVE DEGENERATION; NOREPINEPHRINE; PARKINSON DISEASE; SUPEROXIDE DISMUTASE; TYROSINE 3-MONOOXYGENASE;

EID: 84948420917     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.08.032     Document Type: Article

References (54)

1. V. Annese, M.-T. Herrero, M. Di Pentima, A. Gomez, L. Lombardi, C.M. Ros, V. De Pablos, E. Fernandez-Villalba, and M.E. De Stefano Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism Brain Struct. Funct 2014
2. B.F. Boeve, M.H. Silber, J.E. Parisi, D.W. Dickson, T.J. Ferman, E.E. Benarroch, A.M. Schmeichel, G.E. Smith, R.C. Petersen, J.E. Ahlskog, J.Y. Matsumoto, D.S. Knopman, C.H. Schenck, and M.W. Mahowald Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism Neurology 61 2003 40 45
3. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, Steur EN Jansen, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211
4. A.R. Carta, L. Frau, A. Pisanu, J. Wardas, S. Spiga, and E. Carboni Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model Neuroscience 194 2011 250 261
5. D.Y. Choi, M. Liu, R.L. Hunter, W.A. Cass, J.D. Pandya, P.G. Sullivan, E.J. Shin, H.C. Kim, D.M. Gash, and G. Bing Striatal neuroinflammation promotes Parkinsonism in rats PLoS One 4 2009 e5482
6. G. Costa, L. Frau, J. Wardas, A. Pinna, A. Plumitallo, and M. Morelli MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice Mov. Disord. 28 2013 1957 1965
7. E. Dailly, F. Chenu, B. Petit-Demoulière, and M. Bourin Specificity and efficacy of noradrenaline, serotonin depletion in discrete brain areas of Swiss mice by neurotoxins J. Neurosci. Methods 150 2006 111 115
8. K. Dzirasa, H.W. Phillips, T.D. Sotnikova, A. Salahpour, S. Kumar, R.R. Gainetdinov, M.G. Caron, and M.A. Nicolelis Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony J. Neurosci. 30 2010 6387 6397
9. L.E. Francesca, C. Tirolo, N. Testa, S. Caniglia, M.C. Morale, and B. Marchetti Glia as a turning point in the therapeutic strategy of Parkinson's disease CNS Neurol. Disord. Drug Targets 9 2010 349 372
10. D. Fernández-Suárez, M. Celorrio, J.I. Riezu-Boj, A. Ugarte, R. Pacheco, H. González, J. Oyarzabal, C.J. Hillard, R. Franco, and M.S. Aymerich The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model Neurobiol. Aging 35 2014 2603 2616
11. C.C. Ferrari, and R. Tarelli Parkinson's disease and systemic inflammation Parkinson's Dis. 2011 2011 1 9
12. F. Fornai, M.G. Alessandri, M.T. Torracca, L. Bassi, and G.U. Corsini Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions J. Pharmacol. Exp. Ther. 283 1997 100 107
13. F. Fornai, M.G. Alessandri, M.T. Torracca, L. Bassi, V. Scalori, and G.U. Corsini Noradrenergic modulation of methamphetamine-induced striatal dopamine depletion Ann. NY Acad. Sci. 844 1998 166 177
14. F. Fornai, L. Bassi, M.T. Torracca, M.G. Alessandrì, V. Scalori, and G.U. Corsini Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletionin rodents Neurodegeneration 5 1996 241 249
15. F. Fornai, A.B. di Poggio, A. Pellegrini, S. Ruggieri, and A. Paparelli Noradrenaline in Parkinson's disease: from disease progression to current therapeutics Curr. Med. Chem. 14 2007 2330 2334
16. F. Fornai, F.S. Giorgi, M.G. Alessandri, M. Giusiani, and G.U. Corsini Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses J Neurochem. 72 1999 777 784
17. H.-M. Gao, F. Zhang, H. Zhou, W. Kam, B. Wilson, and J.-S. Hong Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of parkinson's disease Environ. Health Perspect. 119 2011 807 814
18. M. Gesi, P. Soldani, F.S. Giorgia, A. Santinami, I. Bonaccorsi, and F. Fornai The role of the locus coeruleus in the development of Parkinson's disease Neurosci. Biobehav. Rev. 24 2000 655 668
19. F.S. Giorgi, F. Blandini, E. Cantafora, F. Biagioni, M.T. Armentero, L. Pasquali, F. Orzi, L. Murri, A. Paparelli, and F. Fornai Activation of brain metabolism and fos during limbic seizures: the role of locus coeruleus Neurobiol. Dis. 30 2008 388 399
20. A.R. Goazigo, J. Van Steenwinckel, W. Rostene, and S.M. Parsadaniantz Current status of chemokines in the adult CNS Prog. Neurobiol. 104 2013 67 92
21. A.C. Granholm, V. Zaman, J. Godbee, M. Smith, R. Ramadan, C. Umphlet, P. Randall, N.R. Bhat, B. Rohrer, L.D. Middaugh, and H.A. Boger Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous mice Brain Pathol. 21 2011 330 348
22. B. Han, and H. Zhao Effects of hydroxysafflor Yellow A in the attenuation of MPTP neurotoxicity in mice Neurochem. Res. 35 2009 107 113
23. U.-K. Hanisch, and H. Kettenmann Microglia: active sensor and versatile effector cells in the normal and pathologic brain Nat. Neurosci. 10 2007 1387 1394
24. A.S. Harms, J.K. Lee, T.A. Nguyen, J. Chang, K.M. Ruhn, I. Trevino, and M.G. Tansey Regulation of microglia effector functions by tumor necrosis factor signaling Glia 60 2012 189 202
25. M.T. Heneka, F. Nadrigny, T. Regen, A. Martinez-Hernandez, L. Dumitrescu-Ozimek, D. Terwel, D. Jardanhazi-Kurutz, J. Walter, F. Kirchhoff, U.K. Hanisch, and M.P. Kummer Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine Proc. Natl. Acad. Sci. 107 2010 6058 6063
26. M.M. Iravani, M. Sadeghian, S. Rose, and P. Jenner Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss J. Neural Transm. 121 2014 1493 1505
27. V. Jackson-Lewis, M. Jakowec, R.E. Burke, and S. Przedborski Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurodegeneration 4 1995 257 269
28. H.-K. Jeong, I. Jou, and E.-h. Joe Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra. Exp. Mol. Med. 42 2010 823
29. Y. Jia, C. Xu, and Q. Xu Morphological changes of the nigrostriatal pathway in a mouse model of Parkinson's disease Acta Anat. Sin. 43 2012 293 298
30. M. Kohutnicka, E. Lewandowska, I. Kurkowska-Jastrzebska, A. Czlonkowski, and A. Czlonkowska Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Immunopharmacology 39 1998 167 180
31. A.J. Lategan, M.R. Marien, and F.C. Colpaert Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study Life Sci. 50 1992 995 999
32. M. Lee Neurotransmitters and microglial-mediated neuroinflammation Curr. Protein Pept. Sci. 14 2013 21 32
33. A.F. Leentjens, M. Van den Akker, J.F. Metsemakers, R. Lousberg, and F.R. Verhey Higher incidence of depression preceding the onset of Parkinson's disease: a register study Mov. Disord. 18 2003 414 418
34. J. Liu, M.W. Wang, P. Gu, Q.Y. Ma, Y.Y. Wang, Y. Geng, Z.Y. Yuan, D.S. Cui, Z.X. Zhang, L. Ma, B.H. Zhang, M.G. Zhou, and A.P. Zhu Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice Brain Res. 1345 2010 213 220
35. M.R. Marien, F.C. Colpaert, and A.C. Rosenquist Noradrenergic mechanisms in neurodegenerative diseases: a theory Brain Res. Rev. 45 2004 38 78
36. J. Miao, M. Ding, A. Zhang, Z. Xiao, W. Qi, N. Luo, W. Di, Y. Tao, and Y. Fang Pleiotrophin promotes microglia proliferation and secretion of neurotrophic factors by activating extracellular signal-regulated kinase 1/2 pathway Neurosci. Res. 74 2012 269 276
37. Y. Mitsumoto, A. Watanabe, A. Mori, and N. Koga Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice Biochem. Biophys. Res. Commun. 248 1998 660 663
38. R.L. Mosley, J.A. Hutter-Saunders, D.K. Stone, and H.E. Gendelman Inflammation and adaptive immunity in Parkinson's disease Cold Spring Harb. Perspect. Med. 2 2012 a009381
39. G. Paxinos, and K.B.J. Franklin The Mouse Brain in Stereotaxic Coordinates 2001 Academic Press San Diego, CA
40. L. Qian, H.M. Wu, S.H. Chen, D. Zhang, S.F. Ali, L. Peterson, B. Wilson, R.B. Lu, J.S. Hong, and P.M. Flood beta2-Adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway J. Immunol. 186 2011 4443 4454
41. L. Qin, X. Wu, M.L. Block, Y. Liu, G.R. Breese, J.-S. Hong, D.J. Knapp, and F.T. Crews Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration Glia 55 2007 453 462
42. F. Ros-Bernal, S. Hunot, M.T. Herrero, S. Parnadeau, J.C. Corvol, L. Lu, D. Alvarez-Fischer, M.A. Carrillo-de Sauvage, F. Saurini, C. Coussieu, K. Kinugawa, A. Prigent, G. Hoglinger, M. Hamon, F. Tronche, E.C. Hirsch, and S. Vyas Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism Proc. Natl. Acad. Sci. USA 108 2011 6632 6637
43. H. Sawada, R. Hishida, Y. Hirata, K. Ono, H. Suzuki, S.-i. Muramatsu, I. Nakano, T. Nagatsu, and M. Sawada Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine J. Neurosci. Res. 85 2007 1752 1761
44. J. Srinivasan, and W.J. Schmidt Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats Eur. J. Neurosci. 17 2003 2586 2592
45. S. Sugama, L. Yang, B.P. Cho, L.A. DeGiorgio, S. Lorenzl, D.S. Albers, M.F. Beal, B.T. Volpe, and T.H. Joh Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice Brain Res. 964 2003 288 294
46. P. Szot, A. Franklin, C. Sikkema, C.W. Wilkinson, and M.A. Raskind Sequential loss of LC noradrenergic and dopaminergic neurons results in a correlation of dopaminergic neuronal number to striatal dopamine concentration Front. Pharmacol. 3 2012 184
47. P. Szot, C. Miguelez, S.S. White, A. Franklin, C. Sikkema, C.W. Wilkinson, L. Ugedo, and M.A. Raskind A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat Neuroscience 166 2010 279 291
48. P. Teismann, K. Tieu, O. Cohen, D.K. Choi, D.C. Wu, D. Marks, M. Vila, V. Jackson-Lewis, and S. Przedborski Pathogenic role of glial cells in Parkinson's disease Mov. Disord. 18 2003 121 129
49. B. Wang, X. Zou, H. Zhang, D. Duan, L. Ju, X. Jiang, X. Sun, C. Zhao, H. Zhao, J. Guo, C. Xu, E. Gao, and Q. Xu Establishment of an immortalized GABAergic neuronal progenitor cell line from embryonic ventral mesencephalon in the rat Brain Res. 1210 2008 63 75
50. S.-Y. Wu, T.-F. Wang, L. Yu, C.J. Jen, J.-I. Chuang, F.-S. Wu, C.-W. Wu, and Y.-M. Kuo Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway Brain, Behav. Immun. 25 2011 135 146
51. G. Yang, Y. Meng, W. Li, Y. Yong, Z. Fan, H. Ding, Y. Wei, J. Luo, and Z.-J. Ke Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism Brain Pathol. 21 2011 279 297
52. N.R. Zahniser, G.R. Weiner, T. Worth, K. Philpott, R.P. Yasuda, G. Jonsson, and T.V. Dunwiddie DSP4-induced noradrenergic lesions increase beta-adrenergic receptors and hippocampal electrophysiological responsiveness Pharmacol. Biochem. Behav. 24 1986 1397 1402
53. C. Zarow, S.A. Lyness, J.A. Mortimer, and H.C. Chui Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases Arch. Neurol. 60 2003 337 341
54. Y. Zhou, Y. Zhang, J. Li, F. Lv, Y. Zhao, D. Duan, and Q. Xu A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats J Neurochem. 123 2012 771 780